

Universal Biosensors, Inc.
ABN 51 121 559 993

1 Corporate Avenue
Rowville Victoria 3149
Australia

Telephone: +61 3 9213 9000
Facsimile: +61 3 9213 6490
Email: info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

12 March 2015

Universal Biosensors Continues Board Renewal

Universal Biosensors, Inc. (ASX: UBI) announced today a change to its board of directors with the appointment of Ms. Judith Smith as an independent non-executive director and the resignation of Mr. Andrew Jane. This appointment forms part of the board renewal process which has occurred over recent years.

Ms. Smith is a highly experienced investment and funds management executive. During her career, Ms. Smith has worked in a number of investment management roles in the funds management industry, where she has been responsible for evaluating and investing in listed and unlisted companies. Judith is a director of the Australian Renewable Energy Authority, Acorn Capital Investment Fund Ltd (ASX:ACQ), and industry superannuation fund, LUCRF. She was formerly the Head of Private Equity at IFM Investors and Chair of the IFM Risk Committee. Prior to her role at IFM, Judith held various investment management roles including more than a decade at National Mutual Funds Management, where she managed Australian equity research and strategy, as well as Australian equity portfolios.

"Judith has extensive experience in the funds management industry and will be a valuable addition to the Board" said UBI Chairman, Mr Andrew Denver. "We will benefit from her strong risk and corporate governance background and Judith's experience will help us to drive shareholder value. We look forward to her contribution to UBI."

Ms. Smith holds a Master of Applied Finance from the University of Melbourne and a Bachelor of Economics (Honours) from Monash University. Judith is a Fellow of the Financial Services Institute of Australasia, Graduate member of the Australian Institute of Company Directors and was recently awarded the 'Lifetime Contribution Award' by AVCAL (Australian Private Equity and Venture Capital Association) for the significant positive impact she has had on the Australian private equity and venture capital industry.

Whilst welcoming Ms. Smith, UBI Chairman Andrew Denver also acknowledged the important contribution of the outgoing director, Andy Jane. "Mr Jane has been a director of UBI since 2006 prior to UBI's initial public offering and admission to ASX. Since that time Universal Biosensors has transformed from a research and development company to a commercial entity in the growing point-of-care diagnostics market, having relationships with some of the leading healthcare businesses in the world. On behalf of Universal Biosensors, I would like to thank Andy for his commitment and significant contribution to the Company over the past 8 years, and wish him every success with his future", said UBI Chairman, Mr Andrew Denver.

Ends

Enquiries:
Andrew Denver +61 3 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to
<http://www.universalbiosensors.com>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Under applicable United States securities laws all of the shares of our common stock are "restricted securities" as that term is defined in Rule 144 under the Securities Act of 1933, as amended (Securities Act). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.